WASHINGTON — Patients taking once-daily antiepileptic monotherapy had lower healthcare costs than those taking medications with greater dosing frequencies, study findings indicate.
Those initiating medication twice, thrice, and four times daily had 14%, 40.4% and 62.2% higher total annual healthcare costs compared with patients taking once-daily antiepileptic drugs (AEDs), according to a speaker at the American Academy of Neurology 2015 meeting.
“Claims data offer an opportunity to assess the relationship between dosing frequency and healthcare costs from a real-world perspective,” said Fred Grossman, DO, FAPA, senior vice president of clinical development and medical affairs at Sunovion Pharmaceuticals Inc.
“This is big data. This is a study where we looked at retrospective data over a six year period in over 50,000 patients and compared those taking an AED once-daily to those on other dosing frequencies.”
The retrospective analysis included information from 53,338 patients in a large U.S. claims database. The researchers examined the relationship between AED index dosing frequency and annual healthcare costs.
The majority of patients were taking a twice-daily AED (58.5%), followed by thrice-daily (30.2%) and once-daily (11.2%) AED monotherapy. A very small proportion had four-times per day dosing schedule (0.1%).
The adjusted mean per-person annual health care costs increased incrementally for each AED dosing regimen:
- Once daily — $15,385
- Twice daily —$21,806
- Thrice daily —$26,056
- Four times daily — $30,328
“Patients initiating a once-daily AED incurred lower health care costs during the year following monotherapy initiation than patients with greater dosing frequencies,” Grossman said.